Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 28 Aug 24 424B3 Prospectus supplement
- 18 Jun 24 424B3 Prospectus supplement
- 14 Jun 24 424B3 Prospectus supplement
- 31 May 24 424B3 Prospectus supplement
- 20 May 24 424B3 Prospectus supplement
- 14 May 24 424B3 Prospectus supplement
- 28 Mar 24 424B3 Prospectus supplement
- 2 Feb 24 424B3 Prospectus supplement
- 30 Jan 24 424B3 Prospectus supplement
- 19 Jan 24 424B3 Prospectus supplement
- 5 Jan 24 424B3 Prospectus supplement
- 18 Dec 23 EFFECT Notice of effectiveness
- 15 Dec 23 424B3 Prospectus supplement
-
4 Dec 23 S-1/A IPO registration (amended)
- 13 Oct 23 S-3 Shelf registration
GRI similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the inclusion in this Pre-Effective Amendment No. 1 to the Registration Statement of GRI Bio, Inc. (formerly Vallon Pharmaceuticals, Inc.) to Form S-3 on Form S-1 to be filed on or about December 4, 2023 of our report dated February 23, 2023, on our audits of the Vallon Pharmaceutical, Inc. financial statements as of December 31, 2022 and 2021 and for each of the years then ended. Our report includes an explanatory paragraph about the existence of substantial doubt concerning the Company's ability to continue as a going concern. We also consent to the reference to our firm under the caption “Experts” in this Registration Statement.
/s/ EisnerAmper LLP
EISNERAMPER LLP
Iselin, New Jersey
December 4, 2023